Low-Risk Prostate Cancer and Tumor Upgrading to Higher Patterns in the Surgical Specimen. Analysis of Clinical Factors Predicting Tumor Upgrading to Higher Gleason Patterns in a Contemporary Series of Patients Who Have Been Evaluated According to the Modified Gleason Score Grading System

被引:22
作者
Porcaro, Antonio Benito [1 ]
Siracusano, Salvatore [1 ]
De Luyk, Nicolo [1 ]
Corsi, Paolo [1 ]
Sebben, Marco [1 ]
Tafuri, Alessandro [1 ]
Bizzotto, Leonardo [1 ]
Tamanini, Irene [1 ]
Inverardi, Davide [1 ]
Cerruto, Maria Angela [1 ]
Martignoni, Guido [2 ]
Brunelli, Matteo [2 ]
Artibani, Walter [1 ]
机构
[1] Azienda Osped Univ Integrata, Univ Hosp, Osped Policlin, Urol Clin, Verona, Italy
[2] Azienda Osped Univ Integrata, Univ Hosp, Osped Policlin, Dept Pathol, Verona, Italy
关键词
Prostate cancer; Low-risk; Tumor grade; Tumor upgrading; Gleason score system; ACTIVE SURVEILLANCE; RADICAL PROSTATECTOMY; BIOPSY; MEN; DISCREPANCIES; RADIATION; THERAPY; DISEASE; PSA;
D O I
10.1159/000445034
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: To identify clinical factors associated with prostate cancer (PCA) upgrading to higher patterns of the surgical specimen in low-risk PCA. Materials and Methods: We evaluated the records of 438 patients. The multinomial logistic regression model was used. Results: Low-risk PCA included 170 cases (38.8%) and tumor upgrading was detected in 111 patients (65.3%) of whom 72 (42.4%) had pathological Gleason patterns (pGP) = 3 + 4 and 39 (22.9%) pGP > 3 + 4. Prostate-specific antigen (PSA) and proportion of positive cores (P+) were independent predictors of tumor upgrading to higher patterns. The main difference between upgraded cancers related to PSA and to P+ >0.20. The population was stratified into risk classes by PSA <= 5 mu g/l and P+ <= 0.20 (class A), PSA >5 mu g/l and P+ <= 0.20 (class B), PSA <= 5 mu g/l and P+ >0.20 (class C) and PSA > 5 mu g/l and P+0.20 (class D). Upgrading rates to pGP >3 + 4 were extremely low in class A (5.1%), extremely high in D (53.8%). Conclusions: Low-risk PCA is a heterogeneous population with significant rates of undetected high-grade disease. Significant clinical predictors of upgrading to higher patterns include PSA and P+, which identify a very high-risk class that needs repeat biopsies in order to reclassify tumor grade. (C) 2016 S. Karger AG, Basel
引用
收藏
页码:32 / 41
页数:10
相关论文
共 30 条
  • [1] Pathological Upgrading and Up Staging With Immediate Repeat Biopsy in Patients Eligible for Active Surveillance
    Berglund, Ryan K.
    Masterson, Timothy A.
    Vora, Kinjal C.
    Eggener, Scott E.
    Eastham, James A.
    Guillonneau, Bertrand D.
    [J]. JOURNAL OF UROLOGY, 2008, 180 (05) : 1964 - 1967
  • [2] Contemporary Grading for Prostate Cancer: Implications for Patient Care
    Brimo, Fadi
    Montironi, Rodolfo
    Egevad, Lars
    Erbersdobler, Andreas
    Lin, Daniel W.
    Nelson, Joel B.
    Rubin, Mark A.
    van der Kwast, Theo
    Amin, Mahul
    Epstein, Jonathan I.
    [J]. EUROPEAN UROLOGY, 2013, 63 (05) : 892 - 901
  • [3] Quality of Preoperative Biopsy Is a Risk Factor for Positive Surgical Margins in Organ-Confined Prostate Cancer Treated with Nerve-Sparing Robot-Assisted Radical Prostatectomy
    Buetow, Zentia
    Schunk, Stefan
    Janssen, Martin
    Graeber, Stefan
    Saar, Matthias
    Kamradt, Joern
    Siemer, Stefan
    Stoeckle, Michael
    Ohlmann, Carsten-Henning
    [J]. UROLOGIA INTERNATIONALIS, 2015, 95 (04) : 465 - 471
  • [4] Risk of Pathologic Upgrading or Locally Advanced Disease in Early Prostate Cancer Patients Based on Biopsy Gleason Score and PSA: A Population-Based Study of Modern Patients
    Caster, Joseph M.
    Falchook, Aaron D.
    Hendrix, Laura H.
    Chen, Ronald C.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 92 (02): : 244 - 251
  • [5] Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation
    Chun, Felix K. -H.
    Briganti, Alberto
    Shariat, Shahrokh F.
    Graefen, Markus
    Montorsi, Francesco
    Erbersdobler, Andreas
    Steuber, Thomas
    Salonia, Andrea
    Currlin, Eike
    Scattoni, Vincenzo
    Friedrich, Martin G.
    Schlomm, Thorsten
    Haese, Alexander
    Michl, Uwe
    Colombo, Renzo
    Heinzer, Hans
    Friedrich, Martin G.
    Schlomm, Thorsten
    Haese, Alexander
    Michl, Uwe
    Colombo, Renzo
    Heinzer, Hans
    Valiquette, Luc
    Rigatti, Patrizio
    Roehrborn, Claus G.
    Huland, Hartwig
    Karakiewicz, Pierre I.
    [J]. BJU INTERNATIONAL, 2006, 98 (02) : 329 - 334
  • [6] Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
    D'Amico, AV
    Whittington, R
    Malkowicz, SB
    Schultz, D
    Blank, K
    Broderick, GA
    Tomaszewski, JE
    Renshaw, AA
    Kaplan, I
    Beard, CJ
    Wein, A
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (11): : 969 - 974
  • [7] Clinical predictors of upgrading to gleason grade 4 or 5 disease at radical prostatectomy: Potential implications for patient selection for radiation and androgen suppression therapy
    D'Amico, AV
    Renshaw, AA
    Arsenault, L
    Schultz, D
    Richie, JP
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1999, 45 (04): : 841 - 846
  • [8] Dahabreh IJ, 2012, ANN INTERN MED, V156, P582, DOI [10.7326/0003-4819-156-8-201204170-00009, 10.7326/0003-4819-156-8-201204170-00397]
  • [9] The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma
    Epstein, JI
    Allsbrook, WC
    Amin, MB
    Egevad, LL
    Bastacky, S
    Beltrán, AL
    Berner, A
    Billis, A
    Boccon-Gibod, L
    Cheng, L
    Civantos, F
    Cohen, C
    Cohen, MB
    Datta, M
    Davis, C
    Delahunt, B
    Delprado, W
    Eble, JN
    Foster, CS
    Furusato, M
    Gaudin, PB
    Grignon, DJ
    Humphrey, PA
    Iczkowski, KA
    Jones, EC
    Lucia, S
    McCue, PA
    Nazeer, T
    Oliva, E
    Pan, CC
    Pizov, G
    Reuter, V
    Samaratunga, H
    Sebo, T
    Sesterhenn, I
    Shevchuk, M
    Srigley, JR
    Suzigan, S
    Takahashi, H
    Tamboli, P
    Tan, PH
    Têtu, B
    Tickoo, S
    Tomaszewski, JE
    Troncoso, P
    Tsuzuki, T
    True, LD
    van der Kwast, T
    Wheeler, TM
    Wojno, KJ
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2005, 29 (09) : 1228 - 1242
  • [10] A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score
    Epstein, Jonathan I.
    Zelefsky, Michael J.
    Sjoberg, Daniel D.
    Nelson, Joel B.
    Egevad, Lars
    Magi-Galluzzi, Cristina
    Vickers, Andrew J.
    Parwani, Anil V.
    Reuter, Victor E.
    Fine, Samson W.
    Eastham, James A.
    Wiklund, Peter
    Han, Misop
    Reddy, Chandana A.
    Ciezki, Jay P.
    Nyberg, Tommy
    Klein, Eric A.
    [J]. EUROPEAN UROLOGY, 2016, 69 (03) : 428 - 435